Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com.

Our US Research & Development hub, located in the Greater Boston area, brings together the best talent to drive life science innovation. Located in Lexington, Watertown and Cambridge, our teams reflect the full scope of R&D, from early research through late-stage clinical development. We are building for the future by creating a distinct R&D community based on collaboration, partnerships, and cutting-edge research across multiple modalities and therapeutic areas. We recognize that improving human health starts here and that patients rely on us. By combining the speed and agility of biotech with the quality, resources, and stability of a large pharmaceutical company, our US R&D hub will benefit from the best of both worlds to develop new medicines that meet the needs of patients.

Across Novo Nordisk, our people wake up every day knowing their work matters.
From the researcher analysing data, to the manufacturing specialist ensuring quality in every single dose, to the sales professional making sure our treatments reach the people who need them – our people share something powerful: the collective belief that science and innovation can truly transform lives.
It’s not always easy. Breakthroughs take years. Setbacks happen. But knowing that your work could bring hope to millions living with serious chronic diseases. That’s what keeps us going - driving lasting change for long-term health.

  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
75 Hayden Avenue
Lexington, MA 02421
  • Featured Employer
NEWS
Months after partnering with Sanofi on infectious diseases, Germany-based Evotec has formed another significant partnership with Novo Nordisk. The two companies will combine their forces to develop treatments for diabetes, nonalcoholic steatohepatitis (NASH) and other diseases.
Two weeks ago during its quarterly report, Novo Nordisk pointed to positive results in four of 10 Phase IIIa trials with oral semaglutide. This morning, the company revealed that the drug hit the mark in the reduction of blood sugar levels and weight in adults with type 2 diabetes.
Copenhagen, Denmark-based Novo Nordisk acquired Bristol, UK-based Ziylo in a deal that could exceed $800 million.
Here’s a roundup of biopharma companies that have announced hiring trends since the beginning of the year.
Shares of Novo Nordisk are down about five percent this morning after the company reported an overall decline in sales during the second quarter of this year. Sales were particularly disappointing in North America.
Research published in the journal Nature by researchers at the National Health Research Institutes in Taiwan and the National Institute on Aging, National Institutes of Health in the U.S. suggest that a class of diabetes medications known as GLP-1 analogues may be effective treatments for Parkinson’s disease.
President Trump was able to declare a small victory in the arena of drug pricing earlier this week when Pfizer opted to delay its second price-hike of the year. Other companies though have not followed suit and have gone through with price increases for their drugs.
Novo Nordisk’s semaglutide, an oral GLP-1 analogue, continues to rack up positive Phase III clinical trial data compared to its competitors.
New York-based Kallyope and Danish company Novo Nordisk A/S signed a research collaboration and option deal to discover novel therapeutics to treat obesity and diabetes.
JOBS
IN THE PRESS